Abbott launches special programme for babies at high risk for respiratory syncytial virus.
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents / Q000627:therapeutic use*; D006801:Humans; D007231:Infant, Newborn; D007234:Infant, Premature; D000069455:Palivizumab; D011322:Primary Prevention / Q000379:methods; D016730:Program Development; D018357:Respiratory Syncytial Virus Infections / Q000453:epidemiology / Q000517:prevention & control*; D018113:Respiratory Syncytial Virus, Human; D012307:Risk Factors; D013019:South Africa / Q000453:epidemiology
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents; D000069455:Palivizumab